Healthcare [ 11/13 ] | Biotechnology [ 92/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 21, 24 | 0 Increased by +100% | -0.53 Increased by +100% |
| Nov 13, 23 | -0.81 Increased by +61.79% | -0.54 Decreased by -50% |
| Aug 14, 23 | -0.5 Increased by +43.18% | -0.31 Decreased by -61.29% |
| May 8, 23 | -0.58 Increased by +62.82% | 1.82 Decreased by -131.87% |
| Mar 29, 23 | -0.76 Increased by +98.09% | -0.42 Decreased by -80.95% |
| Nov 14, 22 | -2.12 | -0.89 Decreased by -138.2% |
| Aug 15, 22 | -0.88 | -1.07 Increased by +17.76% |
| May 12, 22 | -1.56 | -0.95 Decreased by -64.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 14.96 M Increased by +N/A% | -39.34 M Increased by +57.65% | Decreased by -262.99% Decreased by N/A% |
| Jun 30, 23 | 14.3 M Increased by +N/A% | -23.85 M Increased by +25.67% | Decreased by -166.79% Decreased by N/A% |
| Mar 31, 23 | 17.91 M Increased by +N/A% | -27.02 M Increased by +16.58% | Decreased by -150.82% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -38.99 M Decreased by -88.64% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -92.87 M Decreased by -443.41% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -32.09 M Decreased by -101.49% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -32.38 M Decreased by -187.08% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -20.67 M Decreased by -127.32% | Decreased by N/A% Decreased by N/A% |
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.